US3720760B1 - - Google Patents

Download PDF

Info

Publication number
US3720760B1
US3720760B1 US75813168A US3720760B1 US 3720760 B1 US3720760 B1 US 3720760B1 US 75813168 A US75813168 A US 75813168A US 3720760 B1 US3720760 B1 US 3720760B1
Authority
US
United States
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Priority to US00758131A priority Critical patent/US3720760A/en
Application granted granted Critical
Publication of US3720760A publication Critical patent/US3720760A/en
Assigned to PHARMACIA, INC., A CORP. OF N.J. reassignment PHARMACIA, INC., A CORP. OF N.J. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: PHARMACIA AB, A CORP. OF SWEDEN
Assigned to PHARMACIA AB. reassignment PHARMACIA AB. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: PHARMACIA, INC.
Publication of US3720760B1 publication Critical patent/US3720760B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US00758131A 1968-09-06 1968-09-06 Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples Expired - Lifetime US3720760A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US00758131A US3720760A (en) 1968-09-06 1968-09-06 Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00758131A US3720760A (en) 1968-09-06 1968-09-06 Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples

Publications (2)

Publication Number Publication Date
US3720760A US3720760A (en) 1973-03-13
US3720760B1 true US3720760B1 (fr) 1984-02-07

Family

ID=25050624

Family Applications (1)

Application Number Title Priority Date Filing Date
US00758131A Expired - Lifetime US3720760A (en) 1968-09-06 1968-09-06 Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples

Country Status (1)

Country Link
US (1) US3720760A (fr)

Cited By (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852415A (en) * 1972-10-13 1974-12-03 Hoffmann La Roche Compositions for use in radioimmunoassay as a substitute for blood plasma extract in determination of carcinoembryonic antigen
US3857931A (en) * 1971-02-01 1974-12-31 Hoffmann La Roche Latex polymer reagents for diagnostic tests
US3896217A (en) * 1973-03-19 1975-07-22 Summa Corp Method and apparatus for radioimmunoassay with regeneration of immunoadsorbent
US3959650A (en) * 1974-08-26 1976-05-25 Intelcom Rad Tech Method for detecting and identifying allergy
US4001583A (en) * 1974-10-04 1977-01-04 Barrett M James Covalently bound biological substances to plastic materials and use in radioassay
US4036946A (en) * 1975-10-20 1977-07-19 Marcos Kleinerman Immunofluorometric method for measuring minute quantities of antigens, antibodies and other substances
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US4041146A (en) * 1975-05-01 1977-08-09 General Electric Company Method for detection of biological particles
US4067959A (en) * 1976-05-10 1978-01-10 International Diagnostic Technology, Inc. Indirect solid surface test for antigens or antibodies
US4090850A (en) * 1976-11-01 1978-05-23 E. R. Squibb & Sons, Inc. Apparatus for use in radioimmunoassays
US4133639A (en) * 1975-02-27 1979-01-09 International Diagnostic Technology, Inc. Test article including a covalently attached diagnostic reagent and method
US4144031A (en) * 1976-04-19 1979-03-13 International Radioimmune Systems, Inc. Cell test for detecting human chorionic gonadotropin
US4160016A (en) * 1977-05-16 1979-07-03 Syva Company Receptor fluorescent immunoassay
US4161515A (en) * 1973-10-02 1979-07-17 Syva Company Double receptor fluorescent immunoassay
DE2900546A1 (de) * 1978-01-26 1979-08-30 Miles Lab Spezifische bindungstest-verfahren
US4166844A (en) * 1977-04-18 1979-09-04 E. R. Squibb & Sons, Inc. Solid phase separation technique for use in radioimmunoassays
US4201763A (en) * 1975-10-09 1980-05-06 Bio-Rad Laboratories, Inc. Solid phase immunofluorescent assay method
FR2438844A2 (fr) * 1978-10-12 1980-05-09 Int Diagnostic Tech Procede et appareil d'analyse quantitative par fluorometrie
US4207075A (en) * 1978-08-08 1980-06-10 Liburdy Robert P Rabbit immunoglobulin-N-(3-pyrene)-maleimide conjugate for fluorescent immunoassay
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
WO1980002201A1 (fr) * 1979-04-09 1980-10-16 Minnesota Mining & Mfg Procede de determination de classes d'anticorps d'antigenes specifiques
US4238195A (en) * 1979-01-18 1980-12-09 Miles Laboratories, Inc. Fluorescer-labeled specific binding assays
US4254096A (en) * 1979-10-04 1981-03-03 Bio-Rad Laboratories, Inc. Reagent combination for solid phase immunofluorescent assay
US4256834A (en) * 1979-04-09 1981-03-17 Syva Company Fluorescent scavenger particle immunoassay
US4273756A (en) * 1978-07-28 1981-06-16 Abbott Laboratories Immunoassay for class specific antibodies
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
US4331650A (en) * 1980-07-18 1982-05-25 Science Research Center, Inc. Identification of reagins in the blood serum of allergen sensitized vertebrates
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4343896A (en) * 1975-02-01 1982-08-10 Akzona Incorporated Method and test pack for the demonstration and determination of an antigen or antibody
US4357142A (en) * 1980-07-18 1982-11-02 Akzona Incorporated Glass support coated with synthetic polymer for bioprocess
US4373932A (en) * 1980-01-11 1983-02-15 Akzona Incorporated Application of water-dispersible hydrophobic dyes or pigments as labels in immunoassays
EP0106324A2 (fr) * 1982-10-13 1984-04-25 Minnesota Mining And Manufacturing Company Essai fluorométrique de réactions allergiques et réactifs appropriés
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4486540A (en) * 1980-07-18 1984-12-04 Science Research Center, Inc. Identification of reagins in the blood serum of allergen sensitized vertebrates
FR2547057A1 (fr) * 1983-05-13 1984-12-07 Lofarma Farma Lab Procede pour fixer d'une facon stable des antigenes et des allergenes sur des supports solides, et supports destines a cet usage
WO1985002262A1 (fr) * 1983-11-10 1985-05-23 Ventrex Laboratories, Inc. Matrices portant de multiples allergenes utiles pour un tamisage qualitatif d'allergies
US4528267A (en) * 1982-11-26 1985-07-09 Axionics, Inc. Fluorometirc enzyme inhibition immunoassay for measuring potency of allergen extracts
US4621063A (en) * 1982-10-12 1986-11-04 The Center For Immunological Studies Methods for the detection and quantitation of immunological substances
US4629706A (en) * 1982-02-01 1986-12-16 Miles Laboratories, Inc. Method for determining allergic sensitivity
US4670383A (en) * 1984-09-13 1987-06-02 Boehringer Mannheim Gmbh Immune-chemical measurement process for haptens and proteins
WO1987003692A1 (fr) * 1985-12-03 1987-06-18 Advanced Polymer Systems, Inc. Test reaginique pour la syphilis
US4677067A (en) * 1984-06-22 1987-06-30 Bio-Magnetech Corporation Magnetotactic bacteria in clinical assay, immunoassay, and cell separation procedures and the like
US4696907A (en) * 1980-07-18 1987-09-29 Science Research Center, Inc. Identification of reagins in the blood serum of allergen sensitized vertebrates
EP0245926A2 (fr) * 1986-05-12 1987-11-19 Diagnostic Products Corporation Procédé pour déterminer les antigènes ou les anticorps dans les fluides biologiques utilisant des antigènes ou des anticorps marqués avec un ligand
US4845027A (en) * 1982-10-13 1989-07-04 Minnesota Mining And Manufacturing Company Fluorometric assay of allergic reactions
US4849337A (en) * 1983-01-31 1989-07-18 Minnesota Mining And Manufacturing Company Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody
US4891311A (en) * 1984-02-03 1990-01-02 Abbott Laboratories Stabilized enzyme conjugate composition
US4891321A (en) * 1987-10-21 1990-01-02 Hubscher Thomas T Apparatus for performing determinations of immune reactants in biological fluids
US4935339A (en) * 1985-05-07 1990-06-19 Nichols Institute Diagnostics Delayed solid phase immunologic assay
US5030558A (en) * 1986-11-07 1991-07-09 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
EP0451800A1 (fr) * 1990-04-13 1991-10-16 Abbott Laboratories Attachement d'allergènes à une phase solide
US5098846A (en) * 1987-05-27 1992-03-24 Mclean Hospital Solid phase protein assay by solid phase free site titration
US5132209A (en) * 1987-09-14 1992-07-21 Vanderbeeken Yves E Process for testing for maternal-fetal immunoincompatibility in pregnant women
US5156952A (en) * 1986-11-07 1992-10-20 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US5232835A (en) * 1986-11-07 1993-08-03 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US5244788A (en) * 1992-07-01 1993-09-14 Hubscher Thomas T Method and apparatus for performing determinations of immune rectants in biological fluids
US5429929A (en) * 1991-04-19 1995-07-04 The Trustees Of Columbia University In The City Of New York Method for detecting antibodies to a neuroblastoma antigen in mental illness
US5558869A (en) * 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5622871A (en) * 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US5736343A (en) * 1995-08-18 1998-04-07 Landry; Donald Detection of organic compounds through regulation of antibody-catalyzed reactions
US5877028A (en) * 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
US5879951A (en) * 1997-01-29 1999-03-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing unidirectional flow
US5939252A (en) * 1997-05-09 1999-08-17 Lennon; Donald J. Detachable-element assay device
US5998220A (en) * 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US6187598B1 (en) 1987-04-27 2001-02-13 Conopco Inc. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US6271044B1 (en) 1998-05-06 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method and kit for detecting an analyte
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
EP1195606A1 (fr) * 2000-10-03 2002-04-10 VBC-Genomics Forschungsges.m.b.H. Procédé de dosage d'allergènes avec un micro-réseau
US20020168782A1 (en) * 2001-01-03 2002-11-14 Mccall Catherine A. Detection of allergen-specific IgE
US20030049237A1 (en) * 1996-09-23 2003-03-13 Bannon Gary A. Methods and reagents for decreasing clinical reaction to allergy
US20030129675A1 (en) * 1999-12-23 2003-07-10 Genentech, Inc. Assay method
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US20040208894A1 (en) * 2000-04-06 2004-10-21 Caplan Michael J Microbial delivery system
US6835824B1 (en) 1995-12-29 2004-12-28 University Of Arkansas Peanut allergens and methods
US6855508B2 (en) 1999-11-16 2005-02-15 Genentech, Inc. ELISA for VEGF
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US20050255527A1 (en) * 2004-05-15 2005-11-17 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
US20060099662A1 (en) * 2004-04-16 2006-05-11 Genentech, Inc. Assay for antibodies
US20060182716A1 (en) * 2004-08-09 2006-08-17 Jin Hong Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US20060204473A1 (en) * 2004-08-09 2006-09-14 Blatt Lawrence M Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
WO2008060777A2 (fr) 2006-10-04 2008-05-22 Genentech, Inc. Utilisation de la technique elisa pour rechercher vegf
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
US7405084B1 (en) * 1997-12-30 2008-07-29 Phadia Ab Analytical method using particles and test kit for performing the method
WO2008150525A1 (fr) 2007-06-04 2008-12-11 Genentech, Inc. Anticorps anti-notch 1 spécifiques à nrr et ses procédés d'utilisation
EP2014770A2 (fr) 1997-10-29 2009-01-14 Genentech, Inc. Polypeptide secrété à induction par WNT-1 WISP-2
WO2009012256A1 (fr) 2007-07-16 2009-01-22 Genentech, Inc. Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
EP2033970A2 (fr) 1997-10-29 2009-03-11 Genentech, Inc. Gènes inductibles WNT-1
EP2065467A2 (fr) 2001-02-22 2009-06-03 Genentech, Inc. Anticorps anti-interferon-alpha
WO2010028277A1 (fr) 2008-09-04 2010-03-11 Beckman Coulter, Inc. Activation de la pan-kinase et évaluation de voies de signalisation
US20100166802A1 (en) * 2000-04-06 2010-07-01 Caplan Michael J Methods and reagents for decreasing clinical reaction to allergy
WO2010120561A1 (fr) 2009-04-01 2010-10-21 Genentech, Inc. Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
EP2290087A2 (fr) 2004-12-22 2011-03-02 Genentech, Inc. Méthode de production de protéines multi-membranaires
WO2011028950A1 (fr) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened et ses méthodes d'utilisation
US20110085981A1 (en) * 2008-04-08 2011-04-14 Huiru Wang Glycan-based drugs, therapies and biomarkers
WO2011071577A1 (fr) 2009-12-11 2011-06-16 Genentech, Inc. Anticorps anti-vegf-c et leurs procédés d'utilisation
WO2011079185A1 (fr) 2009-12-23 2011-06-30 Genentech, Inc. Anticorps anti-bv8 et leurs utilisations
US20110183363A1 (en) * 2009-10-26 2011-07-28 Saloumeh Fischer Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
WO2011153346A1 (fr) 2010-06-03 2011-12-08 Genentech, Inc. Imagerie par immuno-tep d'anticorps et d'immunoconjugués et utilisations correspondantes
EP2402373A2 (fr) 2006-01-05 2012-01-04 Genentech, Inc. Anticorps anti-EphB4 et procédés d'utilisation associés
WO2012019024A2 (fr) 2010-08-04 2012-02-09 Immunogen, Inc. Molécules se liant à her3 et leurs immunoconjugués
WO2012030738A2 (fr) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Profils complexes d'activation de phosphoprotéines
WO2012047968A2 (fr) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened et ses procédés d'utilisation
EP2446904A2 (fr) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 anticorps, immuno-conjugués et utilisations associées
EP2468772A2 (fr) 2006-03-16 2012-06-27 Genentech, Inc. Anticorps pour EGFL7 et leurs procédés d'utilisation
WO2012092539A2 (fr) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps contre dll4 et leurs utilisations
EP2474557A2 (fr) 2007-07-16 2012-07-11 Genentech, Inc. Anticorps anti-CD79b, immuno-conjugués et procédés d'utilisation
WO2012149320A1 (fr) 2011-04-29 2012-11-01 Bristol-Myers Squibb Company Schémas posologiques à doses progressivement croissantes d'anticorps anti-ip-10
WO2013078377A1 (fr) 2011-11-23 2013-05-30 Igenica, Inc. Anticorps anti-cd98 et leurs procédés d'utilisation
WO2013142796A2 (fr) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Procédés de traitements au moyen d'anticorps anti-ctla4
WO2013148373A1 (fr) 2012-03-28 2013-10-03 Genentech, Inc. Anticorps idiotypiques anti-hcmv et leurs utilisations
EP2657253A2 (fr) 2008-01-31 2013-10-30 Genentech, Inc. Anticorps anti-CD79b et immuno-conjugués et procédés d'utilisation
WO2013169734A1 (fr) 2012-05-07 2013-11-14 Amgen Inc. Anticorps anti-érythropoïétine
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
WO2014059028A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs méthodes d'utilisation
WO2014122166A1 (fr) 2013-02-06 2014-08-14 Pieris Ag Nouveaux dosages de lipocaline-mutéine pour mesurer la concentration en hepdicine
WO2014160160A2 (fr) 2013-03-13 2014-10-02 Novartis Ag Conjugués anticorps-médicaments
EP2845866A1 (fr) 2006-10-27 2015-03-11 Genentech, Inc. Anticorps et immuno-conjugués et utilisations associées
EP2851372A1 (fr) 2007-11-30 2015-03-25 Genentech, Inc. Anticorps anti-VEGF
WO2015120075A2 (fr) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened et méthodes d'utilisation de celui-ci
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
WO2016024195A1 (fr) 2014-08-12 2016-02-18 Novartis Ag Conjugués médicament-anticorps anti-cdh6
US9267939B2 (en) 2002-07-29 2016-02-23 Abbott Point Of Care Inc. Multiple hybrid immunoassay
WO2016075670A1 (fr) 2014-11-14 2016-05-19 Novartis Ag Conjugués anticorps-médicament
WO2016126972A1 (fr) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened et méthodes d'utilisation de celui-ci
WO2016149537A1 (fr) 2015-03-17 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéine de prion du campagnol roussâtre utilisée comme substrat à large spectre pour détection et discrimination de souches de prions basées sur une conversion induite par agitation en temps réel (rt-quic)
WO2016203432A1 (fr) 2015-06-17 2016-12-22 Novartis Ag Conjugués anticorps-médicament
WO2017040342A1 (fr) 2015-08-28 2017-03-09 Genentech, Inc. Anticorps anti-hypusine et leurs utilisations
WO2017046676A1 (fr) 2015-09-16 2017-03-23 Novartis Ag Anticorps de neutralisation du virus du polyome
WO2017106527A1 (fr) 2015-12-15 2017-06-22 Case Western Reserve University Évaluation de cancer épithélial à l'aide la bêta-défensine
EP3196212A1 (fr) 2010-02-24 2017-07-26 Immunogen, Inc. Anticorps de récepteur 1 de folate et immunoconjugués et leurs utilisations
WO2017136558A1 (fr) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened et méthodes d'utilisation dudit mutant
WO2018136553A1 (fr) 2017-01-18 2018-07-26 Genentech, Inc. Anticorps idiotypiques dirigés contre des anticorps anti-pd-l1 et leurs utilisations
WO2018142322A1 (fr) 2017-02-03 2018-08-09 Novartis Ag Conjugués anticorps-médicament anti-ccr7
US10100121B2 (en) 2012-06-27 2018-10-16 Amgen Inc. Anti-mesothelin binding proteins
US10151754B2 (en) 2014-01-17 2018-12-11 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
WO2019106578A2 (fr) 2017-12-01 2019-06-06 Novartis Ag Anticorps neutralisant les polyomavirus
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
EP3514178A1 (fr) 2013-03-15 2019-07-24 Novartis AG Conjugués anticorps-médicament
WO2019229699A1 (fr) 2018-05-31 2019-12-05 Novartis Ag Anticorps contre l'hépatite b
EP3620467A1 (fr) 2010-03-12 2020-03-11 Debiopharm International SA Molécules de liaison cd37 et immunoconjugués correspondants
WO2020053742A2 (fr) 2018-09-10 2020-03-19 Novartis Ag Anticorps peptidiques anti-hla-vhb
WO2020081493A1 (fr) 2018-10-16 2020-04-23 Molecular Templates, Inc. Protéines de liaison pd-l1
WO2020128863A1 (fr) 2018-12-19 2020-06-25 Novartis Ag Anticorps anti-tnf-alpha
WO2020128612A2 (fr) 2018-12-21 2020-06-25 Novartis Ag Anticorps dirigés contre pmel17 et conjugués de ces derniers
EP3738981A1 (fr) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
EP3888671A2 (fr) 2013-03-11 2021-10-06 Amgen Inc. Formulations protéiques
WO2021222333A1 (fr) 2020-04-30 2021-11-04 Genentech, Inc. Anticorps spécifiques de kras et leurs utilisations
WO2021220199A1 (fr) 2020-04-30 2021-11-04 Novartis Ag Conjugués anticorps-médicament ccr7 pour le traitement du cancer
WO2021247457A2 (fr) 2020-06-01 2021-12-09 Genentech, Inc. Procédés de préparation de vésicules extracellules et leurs utilisations
WO2022081436A1 (fr) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps spécifique du domaine de liaison du récepteur du sars-cov-2 et procédés thérapeutiques
WO2022087274A1 (fr) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps qui neutralisent l'activité de l'interféron de type i (ifn)
WO2022178255A2 (fr) 2021-02-19 2022-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps à domaine unique qui neutralisent le sars-cov-2
WO2022266659A1 (fr) 2021-06-17 2022-12-22 Genentech, Inc. Anticorps anti-ubiquitination et méthodes d'utilisation

Cited By (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228660B1 (en) 1908-04-27 2001-05-08 Conopco Inc. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3857931A (en) * 1971-02-01 1974-12-31 Hoffmann La Roche Latex polymer reagents for diagnostic tests
US3852415A (en) * 1972-10-13 1974-12-03 Hoffmann La Roche Compositions for use in radioimmunoassay as a substitute for blood plasma extract in determination of carcinoembryonic antigen
US3896217A (en) * 1973-03-19 1975-07-22 Summa Corp Method and apparatus for radioimmunoassay with regeneration of immunoadsorbent
US4161515A (en) * 1973-10-02 1979-07-17 Syva Company Double receptor fluorescent immunoassay
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US3959650A (en) * 1974-08-26 1976-05-25 Intelcom Rad Tech Method for detecting and identifying allergy
US4001583A (en) * 1974-10-04 1977-01-04 Barrett M James Covalently bound biological substances to plastic materials and use in radioassay
US4343896A (en) * 1975-02-01 1982-08-10 Akzona Incorporated Method and test pack for the demonstration and determination of an antigen or antibody
US4133639A (en) * 1975-02-27 1979-01-09 International Diagnostic Technology, Inc. Test article including a covalently attached diagnostic reagent and method
US4041146A (en) * 1975-05-01 1977-08-09 General Electric Company Method for detection of biological particles
US4201763A (en) * 1975-10-09 1980-05-06 Bio-Rad Laboratories, Inc. Solid phase immunofluorescent assay method
US4036946A (en) * 1975-10-20 1977-07-19 Marcos Kleinerman Immunofluorometric method for measuring minute quantities of antigens, antibodies and other substances
US4144031A (en) * 1976-04-19 1979-03-13 International Radioimmune Systems, Inc. Cell test for detecting human chorionic gonadotropin
US4067959A (en) * 1976-05-10 1978-01-10 International Diagnostic Technology, Inc. Indirect solid surface test for antigens or antibodies
US4090850A (en) * 1976-11-01 1978-05-23 E. R. Squibb & Sons, Inc. Apparatus for use in radioimmunoassays
US4166844A (en) * 1977-04-18 1979-09-04 E. R. Squibb & Sons, Inc. Solid phase separation technique for use in radioimmunoassays
US4160016A (en) * 1977-05-16 1979-07-03 Syva Company Receptor fluorescent immunoassay
FR2445966A1 (fr) * 1978-01-26 1980-08-01 Miles Lab Procede de normalisation d'un constituant marque
DE2900546A1 (de) * 1978-01-26 1979-08-30 Miles Lab Spezifische bindungstest-verfahren
US4273756A (en) * 1978-07-28 1981-06-16 Abbott Laboratories Immunoassay for class specific antibodies
US4207075A (en) * 1978-08-08 1980-06-10 Liburdy Robert P Rabbit immunoglobulin-N-(3-pyrene)-maleimide conjugate for fluorescent immunoassay
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
FR2438844A2 (fr) * 1978-10-12 1980-05-09 Int Diagnostic Tech Procede et appareil d'analyse quantitative par fluorometrie
US4238195A (en) * 1979-01-18 1980-12-09 Miles Laboratories, Inc. Fluorescer-labeled specific binding assays
US4256834A (en) * 1979-04-09 1981-03-17 Syva Company Fluorescent scavenger particle immunoassay
WO1980002201A1 (fr) * 1979-04-09 1980-10-16 Minnesota Mining & Mfg Procede de determination de classes d'anticorps d'antigenes specifiques
US4236893A (en) * 1979-04-09 1980-12-02 Minnesota Mining And Manufacturing Company Method for the assay of classes of antigen-specific antibodies
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
US4254096A (en) * 1979-10-04 1981-03-03 Bio-Rad Laboratories, Inc. Reagent combination for solid phase immunofluorescent assay
US4373932A (en) * 1980-01-11 1983-02-15 Akzona Incorporated Application of water-dispersible hydrophobic dyes or pigments as labels in immunoassays
US4331650A (en) * 1980-07-18 1982-05-25 Science Research Center, Inc. Identification of reagins in the blood serum of allergen sensitized vertebrates
US4357142A (en) * 1980-07-18 1982-11-02 Akzona Incorporated Glass support coated with synthetic polymer for bioprocess
US4486540A (en) * 1980-07-18 1984-12-04 Science Research Center, Inc. Identification of reagins in the blood serum of allergen sensitized vertebrates
US4696907A (en) * 1980-07-18 1987-09-29 Science Research Center, Inc. Identification of reagins in the blood serum of allergen sensitized vertebrates
US4629706A (en) * 1982-02-01 1986-12-16 Miles Laboratories, Inc. Method for determining allergic sensitivity
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4621063A (en) * 1982-10-12 1986-11-04 The Center For Immunological Studies Methods for the detection and quantitation of immunological substances
EP0106324A2 (fr) * 1982-10-13 1984-04-25 Minnesota Mining And Manufacturing Company Essai fluorométrique de réactions allergiques et réactifs appropriés
EP0106324A3 (en) * 1982-10-13 1986-09-17 Minnesota Mining And Manufacturing Company Fluorometric assay of allergic reactions and reagents therefor
US4845027A (en) * 1982-10-13 1989-07-04 Minnesota Mining And Manufacturing Company Fluorometric assay of allergic reactions
US4528267A (en) * 1982-11-26 1985-07-09 Axionics, Inc. Fluorometirc enzyme inhibition immunoassay for measuring potency of allergen extracts
US4849337A (en) * 1983-01-31 1989-07-18 Minnesota Mining And Manufacturing Company Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody
EP0131546A3 (en) * 1983-05-13 1987-02-04 Laboratorio Farmaceutico Lofarma S.R.L. Method for stably binding antigens and allergens to solid supports and supports obtained
EP0131546A2 (fr) * 1983-05-13 1985-01-16 LABORATORIO FARMACEUTICO LOFARMA s.r.l. Méthode pour lier d'une manière stable des antigènes et des allergènes à polystyrène et supports ainsi obtenus
FR2547057A1 (fr) * 1983-05-13 1984-12-07 Lofarma Farma Lab Procede pour fixer d'une facon stable des antigenes et des allergenes sur des supports solides, et supports destines a cet usage
WO1985002262A1 (fr) * 1983-11-10 1985-05-23 Ventrex Laboratories, Inc. Matrices portant de multiples allergenes utiles pour un tamisage qualitatif d'allergies
US4891311A (en) * 1984-02-03 1990-01-02 Abbott Laboratories Stabilized enzyme conjugate composition
US4677067A (en) * 1984-06-22 1987-06-30 Bio-Magnetech Corporation Magnetotactic bacteria in clinical assay, immunoassay, and cell separation procedures and the like
US4670383A (en) * 1984-09-13 1987-06-02 Boehringer Mannheim Gmbh Immune-chemical measurement process for haptens and proteins
US4935339A (en) * 1985-05-07 1990-06-19 Nichols Institute Diagnostics Delayed solid phase immunologic assay
US4738932A (en) * 1985-12-03 1988-04-19 Advanced Polymer Systems, Inc. Reaginic test for syphilis
WO1987003692A1 (fr) * 1985-12-03 1987-06-18 Advanced Polymer Systems, Inc. Test reaginique pour la syphilis
EP0245926A2 (fr) * 1986-05-12 1987-11-19 Diagnostic Products Corporation Procédé pour déterminer les antigènes ou les anticorps dans les fluides biologiques utilisant des antigènes ou des anticorps marqués avec un ligand
EP0245926A3 (en) * 1986-05-12 1988-05-25 Diagnostic Products Corporation Method of measuring antigens or antibodies in biological fluids using ligand labeled antigens or ligand labeled antibodies
US5156952A (en) * 1986-11-07 1992-10-20 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US5030558A (en) * 1986-11-07 1991-07-09 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US5232835A (en) * 1986-11-07 1993-08-03 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US7109042B2 (en) 1987-04-27 2006-09-19 Inverness Medical Switzerland Gmbh Assays
US5622871A (en) * 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US6187598B1 (en) 1987-04-27 2001-02-13 Conopco Inc. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US6818455B2 (en) 1987-04-27 2004-11-16 Inverness Medical Switzerland Gmbh Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US5656503A (en) * 1987-04-27 1997-08-12 Unilever Patent Holdings B.V. Test device for detecting analytes in biological samples
US5098846A (en) * 1987-05-27 1992-03-24 Mclean Hospital Solid phase protein assay by solid phase free site titration
US5132209A (en) * 1987-09-14 1992-07-21 Vanderbeeken Yves E Process for testing for maternal-fetal immunoincompatibility in pregnant women
US4891321A (en) * 1987-10-21 1990-01-02 Hubscher Thomas T Apparatus for performing determinations of immune reactants in biological fluids
US5494830A (en) * 1987-10-21 1996-02-27 Hubscher; Thomas T. Methods for performing determinations of immune reactants in biological fluids
US7238537B2 (en) 1989-02-17 2007-07-03 Inverness Medical Switzerland Gmbh Assays
US7384796B2 (en) 1989-02-17 2008-06-10 Inverness Medical Switzerland Gmbh Assays
US7407813B2 (en) 1989-02-17 2008-08-05 Inverness Medical Switzerland Gmbh Assays
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US20030143755A1 (en) * 1989-02-17 2003-07-31 Davis Paul James Assays
EP0451800A1 (fr) * 1990-04-13 1991-10-16 Abbott Laboratories Attachement d'allergènes à une phase solide
US5091318A (en) * 1990-04-13 1992-02-25 Abbott Laboratories Binding of allergens to a solid phase
US5429929A (en) * 1991-04-19 1995-07-04 The Trustees Of Columbia University In The City Of New York Method for detecting antibodies to a neuroblastoma antigen in mental illness
US5877028A (en) * 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
US5998220A (en) * 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US6017767A (en) * 1991-05-29 2000-01-25 Beckman Coulter, Inc. Assay device
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5244788A (en) * 1992-07-01 1993-09-14 Hubscher Thomas T Method and apparatus for performing determinations of immune rectants in biological fluids
US5558869A (en) * 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
US5973121A (en) * 1992-12-30 1999-10-26 University Of Arkansas Immunoassay for peanut allergen
US6441142B1 (en) 1992-12-30 2002-08-27 University Of Arkansas Immunoassay for peanut allergen
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5736343A (en) * 1995-08-18 1998-04-07 Landry; Donald Detection of organic compounds through regulation of antibody-catalyzed reactions
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US6835824B1 (en) 1995-12-29 2004-12-28 University Of Arkansas Peanut allergens and methods
US20030049237A1 (en) * 1996-09-23 2003-03-13 Bannon Gary A. Methods and reagents for decreasing clinical reaction to allergy
US7485708B2 (en) 1996-09-23 2009-02-03 University Of Arkansas Nucleic acids encoding ara h 3 polypeptides
US5879951A (en) * 1997-01-29 1999-03-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing unidirectional flow
US5939252A (en) * 1997-05-09 1999-08-17 Lennon; Donald J. Detachable-element assay device
EP2033970A2 (fr) 1997-10-29 2009-03-11 Genentech, Inc. Gènes inductibles WNT-1
EP2014770A2 (fr) 1997-10-29 2009-01-14 Genentech, Inc. Polypeptide secrété à induction par WNT-1 WISP-2
US7405084B1 (en) * 1997-12-30 2008-07-29 Phadia Ab Analytical method using particles and test kit for performing the method
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6271044B1 (en) 1998-05-06 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method and kit for detecting an analyte
US6855508B2 (en) 1999-11-16 2005-02-15 Genentech, Inc. ELISA for VEGF
US7541160B2 (en) 1999-11-16 2009-06-02 David Tai Wai Fei ELISA for VEGF
US20070202558A1 (en) * 1999-11-16 2007-08-30 Genentech, Inc. ELISA for VEGF
US20050233387A1 (en) * 1999-12-23 2005-10-20 Genentech, Inc. Assay method
US20060234306A1 (en) * 1999-12-23 2006-10-19 Genentech, Inc. Assay method
US20030129675A1 (en) * 1999-12-23 2003-07-10 Genentech, Inc. Assay method
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US20100166802A1 (en) * 2000-04-06 2010-07-01 Caplan Michael J Methods and reagents for decreasing clinical reaction to allergy
US20040234548A1 (en) * 2000-04-06 2004-11-25 Caplan Michael J. Microbial delivery system
US8815251B2 (en) 2000-04-06 2014-08-26 Allertein Therapeutics, Llc Microbial delivery system
US8153414B2 (en) 2000-04-06 2012-04-10 Allertein Therapeutics, Llc Microbial delivery system
US20040208894A1 (en) * 2000-04-06 2004-10-21 Caplan Michael J Microbial delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20080139406A1 (en) * 2000-10-03 2008-06-12 Reinhard Hiller Allergen-Microarray Assay
WO2002029415A1 (fr) * 2000-10-03 2002-04-11 Vbc-Genomics Bioscience Research Gmbh Test de jeu ordonne de microechantillons d'allergenes
EP1195606A1 (fr) * 2000-10-03 2002-04-10 VBC-Genomics Forschungsges.m.b.H. Procédé de dosage d'allergènes avec un micro-réseau
CN1325919C (zh) * 2000-10-03 2007-07-11 Vbc-基因组生物科学研究股份公司 过敏原微阵列分析
US20050101031A1 (en) * 2000-10-03 2005-05-12 Reinhard Hiller Allergen-microarray assay
US20020168782A1 (en) * 2001-01-03 2002-11-14 Mccall Catherine A. Detection of allergen-specific IgE
US20050214866A1 (en) * 2001-01-03 2005-09-29 Mccall Catherine A Detection of allergen-specific IgE
EP2065467A2 (fr) 2001-02-22 2009-06-03 Genentech, Inc. Anticorps anti-interferon-alpha
EP2292301A2 (fr) 2001-02-22 2011-03-09 Genentech, Inc. Anticorps anti-interférons-alpha
US9995744B2 (en) 2002-07-29 2018-06-12 Abbott Point Of Care Inc. Multiple hybrid immunoassay
US10641767B2 (en) 2002-07-29 2020-05-05 Abbott Point Of Care Inc. Multiple hybrid immunoassay
US9267939B2 (en) 2002-07-29 2016-02-23 Abbott Point Of Care Inc. Multiple hybrid immunoassay
US20060099662A1 (en) * 2004-04-16 2006-05-11 Genentech, Inc. Assay for antibodies
US20070015228A1 (en) * 2004-04-16 2007-01-18 Genentech, Inc. Assay for Antibodies
US20080176257A9 (en) * 2004-04-16 2008-07-24 Genentech, Inc. Assay for Antibodies
US20050255527A1 (en) * 2004-05-15 2005-11-17 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
US7514223B2 (en) 2004-05-15 2009-04-07 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
US20060182716A1 (en) * 2004-08-09 2006-08-17 Jin Hong Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060204473A1 (en) * 2004-08-09 2006-09-14 Blatt Lawrence M Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
US20100099851A1 (en) * 2004-08-09 2010-04-22 Alios Biopharma, Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
EP2290087A2 (fr) 2004-12-22 2011-03-02 Genentech, Inc. Méthode de production de protéines multi-membranaires
EP2290086A2 (fr) 2004-12-22 2011-03-02 Genentech, Inc. Méthode de production de protéines multi-membranaires
EP2290088A1 (fr) 2004-12-22 2011-03-02 Genentech, Inc. Méthode de production de protéines multi-membranaires
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
EP2402373A2 (fr) 2006-01-05 2012-01-04 Genentech, Inc. Anticorps anti-EphB4 et procédés d'utilisation associés
EP3156418A1 (fr) 2006-01-05 2017-04-19 Genentech, Inc. Anticorps anti-ephb4 et procédés d'utilisation associés
EP2093235A1 (fr) 2006-02-08 2009-08-26 Alios Biopharma Inc. Variantes hyperglycosylées du interferon alfacon-1
EP2468772A2 (fr) 2006-03-16 2012-06-27 Genentech, Inc. Anticorps pour EGFL7 et leurs procédés d'utilisation
EP2447282A2 (fr) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 Anticorps, immuno-conjugués et utilisations associées
EP2446904A2 (fr) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 anticorps, immuno-conjugués et utilisations associées
EP3103812A1 (fr) 2006-10-04 2016-12-14 Genentech, Inc. Elisa pour vegf
EP2457929A1 (fr) 2006-10-04 2012-05-30 Genentech, Inc. ELISA pour VEGF
WO2008060777A2 (fr) 2006-10-04 2008-05-22 Genentech, Inc. Utilisation de la technique elisa pour rechercher vegf
EP2845866A1 (fr) 2006-10-27 2015-03-11 Genentech, Inc. Anticorps et immuno-conjugués et utilisations associées
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
WO2008150525A1 (fr) 2007-06-04 2008-12-11 Genentech, Inc. Anticorps anti-notch 1 spécifiques à nrr et ses procédés d'utilisation
EP2474557A2 (fr) 2007-07-16 2012-07-11 Genentech, Inc. Anticorps anti-CD79b, immuno-conjugués et procédés d'utilisation
WO2009012256A1 (fr) 2007-07-16 2009-01-22 Genentech, Inc. Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
EP2641618A2 (fr) 2007-07-16 2013-09-25 Genentech, Inc. Anticorps anti-CD79B humanisés et immuno-conjugués et procédés dýutilisation
EP2502937A2 (fr) 2007-07-16 2012-09-26 Genentech, Inc. Anticorps anti-CD 79b, immuno-conjugués et procédés d'utilisation
EP3173425A1 (fr) 2007-11-30 2017-05-31 Genentech, Inc. Anticorps anti-vegf
EP2851372A1 (fr) 2007-11-30 2015-03-25 Genentech, Inc. Anticorps anti-VEGF
EP2657253A2 (fr) 2008-01-31 2013-10-30 Genentech, Inc. Anticorps anti-CD79b et immuno-conjugués et procédés d'utilisation
US10342812B2 (en) 2008-04-08 2019-07-09 B&H Biotechnologies, Llc Glycan-based drugs, therapies and biomarkers
US20110085981A1 (en) * 2008-04-08 2011-04-14 Huiru Wang Glycan-based drugs, therapies and biomarkers
US11285166B2 (en) 2008-04-08 2022-03-29 B&H Biotechnologies, Llc Glycan-based drugs, therapies and biomarkers
US9119866B2 (en) * 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
WO2010028277A1 (fr) 2008-09-04 2010-03-11 Beckman Coulter, Inc. Activation de la pan-kinase et évaluation de voies de signalisation
WO2010120561A1 (fr) 2009-04-01 2010-10-21 Genentech, Inc. Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
WO2011028950A1 (fr) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened et ses méthodes d'utilisation
US20110183363A1 (en) * 2009-10-26 2011-07-28 Saloumeh Fischer Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
US9315583B2 (en) 2009-10-26 2016-04-19 Genentech, Inc. Assays for detecting antibodies specific to therapeutic anti-IgE antibodies and their use in anaphylaxis
WO2011071577A1 (fr) 2009-12-11 2011-06-16 Genentech, Inc. Anticorps anti-vegf-c et leurs procédés d'utilisation
WO2011079185A1 (fr) 2009-12-23 2011-06-30 Genentech, Inc. Anticorps anti-bv8 et leurs utilisations
EP3196212A1 (fr) 2010-02-24 2017-07-26 Immunogen, Inc. Anticorps de récepteur 1 de folate et immunoconjugués et leurs utilisations
EP3620467A1 (fr) 2010-03-12 2020-03-11 Debiopharm International SA Molécules de liaison cd37 et immunoconjugués correspondants
WO2011153346A1 (fr) 2010-06-03 2011-12-08 Genentech, Inc. Imagerie par immuno-tep d'anticorps et d'immunoconjugués et utilisations correspondantes
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
WO2012019024A2 (fr) 2010-08-04 2012-02-09 Immunogen, Inc. Molécules se liant à her3 et leurs immunoconjugués
WO2012030738A2 (fr) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Profils complexes d'activation de phosphoprotéines
WO2012047968A2 (fr) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened et ses procédés d'utilisation
WO2012092539A2 (fr) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps contre dll4 et leurs utilisations
WO2012149320A1 (fr) 2011-04-29 2012-11-01 Bristol-Myers Squibb Company Schémas posologiques à doses progressivement croissantes d'anticorps anti-ip-10
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
WO2013078377A1 (fr) 2011-11-23 2013-05-30 Igenica, Inc. Anticorps anti-cd98 et leurs procédés d'utilisation
WO2013142796A2 (fr) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Procédés de traitements au moyen d'anticorps anti-ctla4
US9139659B2 (en) * 2012-03-28 2015-09-22 Genentech, Inc. Idiotypic antibodies and uses thereof
US20130266973A1 (en) * 2012-03-28 2013-10-10 Genentech, Inc. Idiotypic antibodies and uses thereof
WO2013148373A1 (fr) 2012-03-28 2013-10-03 Genentech, Inc. Anticorps idiotypiques anti-hcmv et leurs utilisations
US10513556B2 (en) 2012-05-07 2019-12-24 Amgen Inc. Anti-erythropoietin antibodies
US9441039B2 (en) 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies
WO2013169734A1 (fr) 2012-05-07 2013-11-14 Amgen Inc. Anticorps anti-érythropoïétine
US10919975B2 (en) 2012-06-27 2021-02-16 Amgen Inc. Anti-mesothelin binding proteins
US11866508B2 (en) 2012-06-27 2024-01-09 Amgen Inc. Anti-mesothelin binding proteins
US10100121B2 (en) 2012-06-27 2018-10-16 Amgen Inc. Anti-mesothelin binding proteins
WO2014059028A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs méthodes d'utilisation
WO2014122166A1 (fr) 2013-02-06 2014-08-14 Pieris Ag Nouveaux dosages de lipocaline-mutéine pour mesurer la concentration en hepdicine
EP3888671A2 (fr) 2013-03-11 2021-10-06 Amgen Inc. Formulations protéiques
WO2014160160A2 (fr) 2013-03-13 2014-10-02 Novartis Ag Conjugués anticorps-médicaments
EP3514178A1 (fr) 2013-03-15 2019-07-24 Novartis AG Conjugués anticorps-médicament
US10151754B2 (en) 2014-01-17 2018-12-11 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
EP3738981A1 (fr) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
WO2015120075A2 (fr) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened et méthodes d'utilisation de celui-ci
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
WO2016024195A1 (fr) 2014-08-12 2016-02-18 Novartis Ag Conjugués médicament-anticorps anti-cdh6
WO2016075670A1 (fr) 2014-11-14 2016-05-19 Novartis Ag Conjugués anticorps-médicament
WO2016126972A1 (fr) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened et méthodes d'utilisation de celui-ci
WO2016149537A1 (fr) 2015-03-17 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéine de prion du campagnol roussâtre utilisée comme substrat à large spectre pour détection et discrimination de souches de prions basées sur une conversion induite par agitation en temps réel (rt-quic)
WO2016203432A1 (fr) 2015-06-17 2016-12-22 Novartis Ag Conjugués anticorps-médicament
WO2017040342A1 (fr) 2015-08-28 2017-03-09 Genentech, Inc. Anticorps anti-hypusine et leurs utilisations
EP3932953A1 (fr) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anticorps anti-hypusine et leurs utilisations
WO2017046676A1 (fr) 2015-09-16 2017-03-23 Novartis Ag Anticorps de neutralisation du virus du polyome
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
US11066472B2 (en) 2015-09-29 2021-07-20 Amgen Inc. Methods of treating cardiovascular disease with an anti-ASGR antibody or binding fragments thereof
US10816549B2 (en) 2015-12-15 2020-10-27 Case Western Reserve University Epithelial cancer evaluation using beta defensin
WO2017106527A1 (fr) 2015-12-15 2017-06-22 Case Western Reserve University Évaluation de cancer épithélial à l'aide la bêta-défensine
WO2017136558A1 (fr) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened et méthodes d'utilisation dudit mutant
WO2018136553A1 (fr) 2017-01-18 2018-07-26 Genentech, Inc. Anticorps idiotypiques dirigés contre des anticorps anti-pd-l1 et leurs utilisations
US11279762B2 (en) 2017-01-18 2022-03-22 Genentech, Inc. Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
WO2018142322A1 (fr) 2017-02-03 2018-08-09 Novartis Ag Conjugués anticorps-médicament anti-ccr7
WO2019106578A2 (fr) 2017-12-01 2019-06-06 Novartis Ag Anticorps neutralisant les polyomavirus
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
WO2019229699A1 (fr) 2018-05-31 2019-12-05 Novartis Ag Anticorps contre l'hépatite b
WO2020053742A2 (fr) 2018-09-10 2020-03-19 Novartis Ag Anticorps peptidiques anti-hla-vhb
WO2020081493A1 (fr) 2018-10-16 2020-04-23 Molecular Templates, Inc. Protéines de liaison pd-l1
WO2020128863A1 (fr) 2018-12-19 2020-06-25 Novartis Ag Anticorps anti-tnf-alpha
WO2020128612A2 (fr) 2018-12-21 2020-06-25 Novartis Ag Anticorps dirigés contre pmel17 et conjugués de ces derniers
WO2021220199A1 (fr) 2020-04-30 2021-11-04 Novartis Ag Conjugués anticorps-médicament ccr7 pour le traitement du cancer
WO2021222333A1 (fr) 2020-04-30 2021-11-04 Genentech, Inc. Anticorps spécifiques de kras et leurs utilisations
WO2021247457A2 (fr) 2020-06-01 2021-12-09 Genentech, Inc. Procédés de préparation de vésicules extracellules et leurs utilisations
WO2022081436A1 (fr) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps spécifique du domaine de liaison du récepteur du sars-cov-2 et procédés thérapeutiques
WO2022087274A1 (fr) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps qui neutralisent l'activité de l'interféron de type i (ifn)
WO2022178255A2 (fr) 2021-02-19 2022-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps à domaine unique qui neutralisent le sars-cov-2
WO2022266659A1 (fr) 2021-06-17 2022-12-22 Genentech, Inc. Anticorps anti-ubiquitination et méthodes d'utilisation

Also Published As

Publication number Publication date
US3720760A (en) 1973-03-13

Similar Documents

Publication Publication Date Title
US3720760B1 (fr)
AU428130B2 (fr)
AU5184069A (fr)
AU6168869A (fr)
AU6171569A (fr)
AU416157B2 (fr)
AU429879B2 (fr)
AU4811568A (fr)
AU421558B1 (fr)
AU3224368A (fr)
AU3789668A (fr)
BE709301A (fr)
BE709415A (fr)
BE709095A (fr)
BE708951A (fr)
BE708933A (fr)
BE708888A (fr)
BE720948A (fr)
BE642636A (fr)
BE630165A (fr)
BE581157A (fr)
BE709138A (fr)
BE709274A (fr)
AU5758767A (fr)
BE724258A (fr)

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHARMACIA AB., RAPSGATEN 7, UPPSALA, SWEDEN, A COM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:PHARMACIA, INC.;REEL/FRAME:004143/0253

Effective date: 19830622

B1 Reexamination certificate first reexamination
PS Patent suit(s) filed
CCB Certificate of correction for reexamination